World's Best Scientists 2026 revealed!
Ramesh K. Ramanathan

Ramesh K. Ramanathan

D-Index & Metrics

Medicine

D-Index
86
Citations
42064
World Ranking
13873
National Ranking
7041

Ramesh K. Ramanathan publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ramesh K. Ramanathan sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 473 publications — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ramesh K. Ramanathan D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ramesh K. Ramanathan sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ramesh K. Ramanathan is affiliated with the Mayo Clinic in the United States and has contributed extensively to the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their research spans several specialized areas, including Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Biomaterials.

Their work primarily focuses on key topics such as:

  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Nanoparticle-Based Drug Delivery
  • Cancer Treatment and Pharmacology
  • Gastric Cancer Management and Outcomes
  • PI3K/AKT/mTOR signaling in cancer
  • Lung Cancer Treatments and Mutations

Ramanathan has published research in several notable venues, including:

  • UNC Libraries
  • Journal of Clinical Oncology
  • Targeted Oncology
  • Molecular Cancer Therapeutics
  • British Journal of Clinical Pharmacology

Their recent publications demonstrate a focus on clinical trials and targeted therapies in cancer treatment. Some significant papers include:

  • A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer, 2023, Journal of Clinical Oncology
  • Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours, 2020, British Journal of Clinical Pharmacology
  • Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer, 2020, Targeted Oncology
  • Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors, 2020, Molecular Cancer Therapeutics
  • Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors, 2021, Molecular Cancer Therapeutics

Ramanathan frequently collaborates with other researchers, including:

  • Daniel D. Von Hoff
  • Richard M. Goldberg
  • Daniel J. Sargent
  • Roscoe F. Morton
  • Charles S. Fuchs

Best Publications

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

    Richard M. Goldberg;Daniel J. Sargent;Roscoe F. Morton;Charles S. Fuchs

  • Outcomes After Laparoscopic Roux-en-Y Gastric Bypass for Morbid Obesity

    Philip R. Schauer;Sayeed Ikramuddin;William Gourash;Ramesh Ramanathan

  • Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus.

    Philip R Schauer;Bartolome Burguera;Sayeed Ikramuddin;Dan Cottam

  • Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07

    J. Philip Kuebler;H. Samuel Wieand;Michael J. O'Connell;Roy E. Smith

  • Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

    Daniel D. Von Hoff;Ramesh K. Ramanathan;Mitesh J. Borad;Daniel A. Laheru

  • Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

    Howard S. Hochster;Lowell L. Hart;Ramesh K. Ramanathan;Barrett H. Childs

  • Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

    Mace L. Rothenberg;Amit M. Oza;Robert H. Bigelow;Jordan D. Berlin

  • Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

    Patrick J. Loehrer;Yang Feng;Higinia Cardenes;Lynne Wagner

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor

  • Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

    William D Tap;Zev A Wainberg;Stephen P Anthony;Prabha N Ibrahim

  • Surgically-Induced Weight Loss Significantly Improves Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome

    Samer G. Mattar;Laura M. Velcu;Mordechai Rabinovitz;A J. Demetris

  • Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis

    Bodour Salhia;Jeff Kiefer;Julianna T. D. Ross;Raghu Metapally

  • Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741

    Hanna K. Sanoff;Daniel J. Sargent;Megan E. Campbell;Roscoe F. Morton

  • A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

    Helmut Oettle;D. Richards;R. K. Ramanathan;J. L. van Laethem

  • Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

    Johann de Bono;Ramesh K. Ramanathan;Lida Mina;Rashmi Chugh

  • Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

    Rachna T. Shroff;Milind M. Javle;Lianchun Xiao;Ahmed O. Kaseb

  • Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Davendra P.S. Sohal;Pamela B. Mangu;Alok A. Khorana;Manish A. Shah

  • A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

    Ramesh K. Ramanathan;Chandra P. Belani;Deepti A. Singh;Michael Tanaka

Frequent Co-Authors

Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute
Chandra P. Belani
Chandra P. Belani Penn State Cancer Institute
Jeffrey R. Infante
Jeffrey R. Infante Janssen (Belgium)
David Goldstein
David Goldstein University of New South Wales
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Patricia LoRusso
Patricia LoRusso Yale University
Howard S. Hochster
Howard S. Hochster Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a medical career in the USA, there are many alternative online degrees and career pathways that can complement or provide entry into the healthcare field. One popular route is through medical billing and coding schools that accept financial aid, which allow individuals to begin working in healthcare administration without incurring high upfront costs.

For those interested in direct patient care but wanting to streamline the admissions process, consider nursing schools that don't require teas or hesi. These programs can make it easier and faster to start your nursing education by removing standardized testing barriers.

Additionally, growing demand for healthcare leaders has increased interest in healthcare administration degrees, which can often be completed online at an accelerated pace. For registered nurses aiming to advance their careers, adn to np bridge programs offer a direct path to becoming a nurse practitioner.

These flexible educational options can help you gain valuable skills, meet evolving healthcare demands, and progress within various medical career pathways in the United States.

Best Scientists Citing Ramesh K. Ramanathan

Trending Scientists

Recently Published Articles